Table 4 Effects of pirfenidone and guideline-recommended drugs on post-myocardial infarction (MI) remodeling and its single motives.
From: Cardiac protection by pirfenidone after myocardial infarction: a bioinformatic analysis
Treatment | Post-MI remodelling | Cardiomyocyte cell death | Impaired cardiomyocyte contractility | ECM remodeling and fibrosis | Hypertrophy | Inflammation | RAAS activation |
|---|---|---|---|---|---|---|---|
Pirfenidone (only targets) | 34% | 70% | 24% | 14% | 19% | 25% | 16% |
Pirfenidone (targets + bioflags) | 49% | 71% | 73% | 71% | 77% | 70% | 71% |
ACEi | 81% | 5% | 3% | 72% | 77% | 3% | 77% |
ARB | 78% | 57% | 31% | 33% | 86% | 36% | 85% |
Beta-blockers | 68% | 24% | 74% | 7% | 73% | 3% | 81% |
MRA | 74% | 72% | 12% | 12% | 82% | 5% | 3% |
